Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem presented as an intravenous formulation for injection use. It treats serious bacterial infections, including intra‑abdominal infections, pneumonia, meningitis, urinary tract infections, and sepsis, in adult and pediatric patients as prescribed by a qualified clinician.

GNH USA supplies Meropenem Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic indicated for severe bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure. - Complicated urinary tract infections: eliminates causative pathogens and resolves infection. - Nosocomial pneumonia: provides effective coverage against resistant respiratory pathogens. - Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections. - Severe sepsis and septic shock: rapidly reduces bacterial load to support hemodynamic recovery.

Adverse reactions may occur with Meropenem therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in transaminases. - Injection site phlebitis: local irritation at IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Anaphylaxis: acute hypersensitivity reaction. - Severe neutropenia: marked reduction in white blood cells. - Acute renal impairment: worsening kidney function. - Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Careful assessment and monitoring are required when using Meropenem.

- Renal impairment: adjust dose based on creatinine clearance. - Hypersensitivity: avoid in patients with known carbapenem allergy. - Pregnancy and lactation: use only if benefit outweighs potential risk; data are limited. - Seizure risk: monitor neurologic status, especially in patients with CNS disorders. - Concomitant nephrotoxic drugs: increase monitoring of renal function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Valproic acid: carbapenems can reduce serum valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, heightening toxicity. - Warfarin: carbapenems can enhance anticoagulant effect, increasing INR.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of meropenem. - Aminoglycosides: combined nephrotoxicity risk. - Other nephrotoxic agents: monitor kidney function closely. - Anticonvulsants (other than valproate): may require dose adjustments. - Oral contraceptives: potential reduction in efficacy, advise alternative contraception.